186) However, their impact on patient outcomes has not been demonstrated |
187) uld engage positively with SNS to improve patient outcomes or create more patient-le |
188) harmacy resident contributed to improving patient outcomes while reducing utilizatio |
189) large randomized control trial looked at patient outcomes with strategies of early |
190) ged in a timely manner to improve overall patient outcomes. |
191) isual analog scale was used to assess the patient-reported outcomes. |
192) It results in high patient satisfaction rates and modest impr |
193) Mean patient satisfaction was 8·3 ± 0·5 |
194) ed with negligible complications and high patient satisfaction was maintained during |
195) was to evaluate the clinical success and patient satisfaction when dental implant-r |
196) Other variables that could influence patient satisfaction with this therapy wer |
197) ptom and functional improvement with high patient satisfaction. |
198) benefits in the delivery of drug to some patient groups such as pediatrics. |
199) Between the patient groups with and without coronary t |
200) e treatment of falciparum malaria for all patient groups. |
201) m the efficacy of anidulafungin for these patient groups. |
202) due to different voice pathologies in the patient groups. |
203) of €12 300, €18 137 and €11 330 per patient in France, Germany and the UK, res |
204) cost of €7984, €7517 and €8860 per patient in France, Germany and the UK, res |
205) 3fs mutation, confirming the first LGMD2A patient in Taiwan. |
206) ngs, lack of a real relationship, placing patient in parental role, and failure to p |
207) and psychiatrists described an adolescent patient in their care based on all availab |
208) In the case described, the patient presented for dental treatment wit |
209) follow-up 19 month post-operatively, the patient presented pain-free without functi |
210) In this case report, the patient presented with a deficiency in bot |
211) A patient presented with fatigue, generalize |
212) A patient presented with such an infective c |
213) Patient MSCs comparatively exhibited i) se |
214) Considering that patient MSCs exhibited phenotypic changes, |
215) The transcriptional profile of patient MSCs isolated 6 months posttranspl |
216) al and functional alterations observed in patient MSCs. |
217) Patient education concerning HIV and antir |
218) ve pulmonary disease (n = 52) following a patient education course. |
|